NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer

Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

The ruling applies to patients who are less than one year from completing treatment with Roche’s Herceptin (trastuzumab) following surgery, where Herceptin is the only HER2-directed therapy the patient has received. It has been estimated that this means that around 1,600 people in England and Wales will be eligible to receive the therapy.

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.